AL101 A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s

NCT06079190

A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease

Associated Conditions

Alzheimers

Principal Investigator

Sponsor

Glaxo Smith Kline

We are conducting this research study to find out if study drug GSK4527226 [AL101], a drug being developed by GSK together with another company called Alector, can reduce the loss of memory and decline in daily functioning usually seen in early Alzheimer’s disease (AD), and whether it is safe and well tolerated. This study will include adults who are between 50 and 85 years of age with early AD. You have been invited to participate because you have symptoms of memory loss associated with early AD.

This study is currently enrolling.